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Summary.-Maturation of monocytes into macrophages in vitro has been assayed
by a quantitative microtitre assay in patients with squamous-cell carcinoma of the
lung. Monocyte maturation in autologous serum was significantly depressed in
patients with both limited and extensive disease compared with normal controls,
patients with chronic obstructive airways disease and controls matched for age, sex,
smoking history, respiratory function and the presence of infection. Maturation of
monocytes from patients with terminal non-malignant disease was depressed,
though not to the same extent as in those with extensive malignancy. Monocytes
from relatives of patients with squamous-cell carcinoma of the lung matured
normally.
In 10 patients with limited disease, in vitro monocyte maturation was repeated
6-12 weeks after operation, and was found to relate to prognosis.
THE FIRST SUGGESTION that macro-
phages might participate as effectors in
tumour-cell destruction was made by
Gorer (1961) on the basis of morphological
studies of ascitic tumours in mice. Since
that time there has been increasing
evidence that cells of the mononuclear
phagocyte system (MPS) may be im-
portant in natural surveillance against
malignant cells. Nude mice, devoid of a
T-lymphocyte system, do not have an
increased frequency of all spontaneous
tumours, as would be anticipated if an
immunological surveillance mechanism
were based on the T cell (Outzen et al.,
1975). In fact, the incidence of tumours is
diminished, which could be explained if
the macrophage were the important anti-
tumour effector cell, since macrophage
function is "activated" in these animals
(Cheers & Waller, 1975).
The resistance of animals to challenge
with tumours may be influenced by alter-
ing the function of the MPS in vivo
(Tevethia et al., 1976; Isa & Sanders,
1975). Macrophages from animals treated
with MPS activators can be shown to
possess the potential for tumour-cell cyto-
toxicity (Hibbs, 1976), as can the macro-
phages extracted from animal tumours
(Holden et al., 1976). Recent work has
extended these findings to human mono-
cytes and macrophages (Mantovani et al.,
1979) and to macrophages isolated from
human tumours (Vose, 1978). Macrophages
are often present in considerable numbers
within tumours (Evans, 1972) and in some
cases their number has been inversely
related to the metastatic potential of the
tumour (Lauder et al., 1977).
As a result of this work suggesting
importance of the MPS in defence against
malignancy, there has been considerable
interest in the function of cells of this
system in tumour-bearing hosts. The abso-
lute number of peripheral-blood mono-
cytes is normal or increased (Barrett
1970), as is their number as a proportion
of all mononuclear cells (Rhodes, 1977a).
Metabolic activity (King et al., 1977), in
vivo phagocytic capacity (Margarey &
Baum, 1977) and Fc-receptor expressionMONOCYTE MATURATION
(Rhodes, 1 977b) are increased but, con-
versely, migration in vivo (Dizon &
Southam, 1963) and in vitro (Snyderman
et al., 1977) is decreased. Monocyte pro-
duction from marrow in animals is in-
creased (Meuret et al., 1977) but recent
reports suggest that the ability of mono-
cytes to mature into macrophages in vitro
is reduced (Currie & Hedley, 1977; Taylor
& Currie, 1979). This lack of ability to
mature has been shown to be related to
prognosis in primary breast cancer (Taylor
& Currie, 1979) and to be restored by
treatment with Corynebacteriurn parvurn
in patients with malignant melanoma
(Hedley et al., 1979).
The aim of this study was to quantitate
in vitro maturation of monocytes from
patients with squamous-cell carcinoma
(SCC) of the lung and from controls
(normal volunteers and patients with non-
malignant disease). In addition, the effect
of severe debility has been investigated
and a group of first-degree relatives
studied.
PATIENTS, MATERIALS AND METHODS
Patients. The study group comprised
patients with squamous-cell carcinoma (SCC)
ofthe lung admitted to Brompton or London
Chest Hospitals during the period June 1978
to November 1979. They were investigated
by the physician under whose care they had
been admitted. Tests included a full blood
count, electrolyte and urea measurements,
liver-function tests, chest radiography and a
variety of the following: tomography; liver,
bone and brain nuclear scans; computerized
axial tomography; sputum cytology; fibre-
optic bronchoscopy; rigid bronchoscopy and
needle-aspiration biopsy. History and clinical
examination, with the results of these in-
vestigations, made it possible to classify the
patients as having limited disease (confined
to ipsilateral lung with or wvithout hilar nodes)
or extensive disease (involving the medias-
tinum, contralateral lung or supraclavicular
nodes, with or without distant metastases).
Classification of the tumours as squamous
was based on cytological examination of the
sputum (12 patients), histology of biopsy
material (25) and resection specimens (3). All
patients were considered to have definite
SCC, the specimens showing keratinization
and, in the majority, intercellular bridges
(Kreyberg et al., 1967). A number of patients
were taking bronchodilator therapy, and a
few were being treated with antibiotics for
clinically diagnosed episodes of infection.
Forty patients were studied:
Group 1-20 with limited disease
Group 2-20 patients with extensive disease
Control Groups 113 control subjects were
assessed and these w%Aere divided into the
following groups:
Group 3 10 normal non-smokers, aged
25-35
Group 4 10 normal non-smokers, aged
53-78
Group 5-40 normal smokers, aged 43-75.
Subjects in Groups 3 to 5 were volunteers
from the staffofBrompton Hospital and from
a local general practice.
Group 6 21 patients with chronic obstruc-
tive airways disease (COAD).
These were studied while in hospital for
assessment. They all met the Medical
Research Council's definition of chronic
bronchitis (Medical Research Council, 1965);
in addition, 2 had evidence of destructive
emphysema, bothclinicallyand radiologically.
Seventeen werereceiving a variety ofbroncho-
dilators and 13 were taking inhaled cortico-
steroids. Patients taking systemic cortico-
steroids were excluded from the study.
Group 7-12 patients with COAD suffering
from acute infective episodes.
Apart from the presence of infection these
patients were in every way similar to those in
Group 6. They all had chronic bronchitis and
one had evidence of destructive emphysema.
In only 2 cases did sputum culture grow a
pathogenic organism. The patients were all
receiving antibiotics at the time of the study
but, although 9 were receiving bronchodilator
therapy and 7 inhaled corticosteroids, none
was receiving systemic corticosteroids.
Group 8-10 seriously ill patients with non-
malignant disease.
These patients were studied in order to
assess the effect of debility and advanced
metabolic disturbance on tests of monocyte
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function. Three had terminal pneumonia, 3
severe cardiac failure unresponsive to treat-
ment, 2 advanced cirrhosis of the liver and
the remaining 2 cystic fibrosis with marked
hypoalbuminaemia, infection and wasting.
They were receiving a variety of drugs, but
once again patients taking systemic cortico-
steroids were excluded.
Group 9-10 relatives of patients with SCC
ofthe lung.
First-degree relatives, siblings and children
ofthe index patients were studied. They were
all healthy at the time of the study and
receiving no drug therapy.
Group 10-10 patients were re-studied after
surgical resection of their primary
tumour.
They were investigated no sooner than 6
weeks, and no later than 12 weeks after their
operation.
Groups 11 and 12-In addition, each
patient with cancer was compared with a
subject from one of the control groups,
matched for sex, age (within the same
decade), respiratory function (<50%,
50-75%, >75% of predicted; Cotes,
1975), forced expiratory volume (FEV1)
or forced vital capacity (FVC), which-
ever was least, as assessed by dry spiro-
metry (vitalograph), smoking habit (pre-
sent smoker, ex-smoker for more than 6
months, non-smoker) and the presence
ofinfection.
Clinical details of all patients and controls
are summarized in Table I.
Monocyte maturation.-This was based on
the assay described by Currie & Hedley
(1977). Blood was drawn between 08:30 and
11:00 and the sample divided into 2. The
first 30 ml was allowed to clot in sterile plastic
universals and the serum separated. Any
serum not used the same day was stored at
-70°C in lml aliquots. The second 30 ml of
blood was defibrinated, diluted 1:1 with
phosphate-buffered saline (PBS) and layered
on a fresh mixture of Ficoll 400 (Pharmacia
Fine Chemicals, Uppsala, Sweden) and
Triosil 440 (Nyegaard and Company, Oslo,
Norway) having a final specific gravity of
1-077. After centrifugation at 500 g for 35 min
at room temperature, mononuclear cells lying
at the interface of serum and Ficoll-Triosil
were harvested and washed x 4 in Medium
TABLE I.-Clinical details ofpatients with squamous-cell carcinoma ofthe lung and control
groups
Group (n)
1. Limited SCC
(20)
2. Extensive SCC
(20)
3. Non-smokers
(10)
4. Non-smokers
(10)
5. Smokers
(40)
6. COAD
(21)
7. COAD with
infection (12)
8. Terminal NMD
(10)
9. Relatives
M:F Age*
18:2 63 9
(50-76)
17:3 66 3
(57-81)
9:1 28-2
(25-35)
8:2 63 4
(55-78)
30:10 61 8
(32-75)
17:4 66 0
(51-80)
9:3 68 0
(49-77)
7:3 50 9
(18-78)
7:3 52-6
(32-68)
Cigarettest
52 1
(20-100)
48-2
(6-140)
41 7
(15-100)
47.4
(14-100)
44 0
(15-80)
18 2
(0-44)
15 9
(0-40)
FEV1
75 1
(25-5-103)
65*3
(28-101)
98 5
(85-105)
95.7
(82-124)
97 0
(81-113)
53.4
(21-94)
60 6
(21-101)
53-6
(7.7-98)
98 8
(90-110)
FVC
81 4
(504-100)
71 3
(45-100)
101-2
(95-104)
98 3
(75-104)
96 1
(75-110)
66*7
(41-100)
74*6
(25-100)
66 2
(26-7-100)
99-6
(83-102)
* Mean years (range).
tMean pack years (range).
I Assessed clinically.
COAD =chronic obstructive airways disease.
NMD =non-malignant disease.
FEV1=forced expiratory volume in one second (% predicted).
FVC=forced vital capacity (% predicted).
Infected
patientst
4
3
12
2
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199 (M199, Wellcome, Beckenham). After a
final wash in RPMI 1640 (Flow Laboratories.
Irvine) supplemented with L-glutamine 2 mar,
penicillin 100 u/ml, streptomycin 100 ,ug/ml
and HEPES buffer (Gibeo Europe, Glasgow)
tD a final concentration of 0-02 M. the cells
-iere counted and adjusted to a final concen-
tration of 4x 106/ml in RPMI 1640. Sterile
siliconized glassware wi-as used throughout the
separation procedure. Only cell preparations
with >95% viability by trypan-blue ex-
clusion were used in this study.
Fifty microlitres of cell suspension and
50 ,l of serum were added to the wNells of
microtitre plates (Nunclon Delta, Denmark)
and incubated at 37°C in a humidified
atmosphere of 50o CO2 in air. Cytospin prep-
arations (Shandon Southern) were made of
the same cell suspensions for histochemical
staining. These were fixed with cold buffered
formol acetone for 15 sec, air-dried and
stained for nonspecific esterase activity (NSE)
at pH 6-3, as described by Yam et al. (1970).
From these preparations. counts of the per-
centage monocytes were made, a total of 300
cells being counted in each case.
At 7 days each well was washed x 3 with
RPMI 1640 to remove non-adherent cells and
the nuclei of the remaining adherent cells
were released and stained by adding 50 ,ul of
0-lM citric acid containing 1:2000 crystal
violet (Sanford et al., 1951). After 30 min the
solution in each well was mixed vigorously
and the number ofnuclei counted in a haema-
cytometer. Monocyte maturation was then
expressed as the percentage of monocytes
placed in culture at Day 1 which were present
as mature adherent macrophages at Day 7.
The mean of 5 replicate w-ells was taken in
each case.
Except for relatives and patients with
severe non-malignant disease, who were
tested once only, all patients and normal
controls were tested on two separate occasions
within 3 days of each other, and the mean
taken.
Monocyte adherence. Two microlitres of
mononuclear cells in RPMI 1640 containing
5000 autologous serum prepared as above
were placed in each of 10 -xNells ofa microtitre
plate and incubated for 2 h at 37°C in a
humidified atmosphere of50o CO2 in air. Each
well was washed x 3 with RPMI 1640, and
the cells adhering to the bottom of each well
counted. The mean of 10 wells wNas taken and
the result expressed as a number of cells
adherent at 2 h as a percentage of NSE+ cells
originally placed in each well.
Statistical analysis of data. The Mann-
Whitney U test and the Wilcoxon ranked-
pair test were used for comparing differences
bet-ween groups or changes -within groups.
The Spearman rank-correlation test was
employed for determining the significance of
correlations betw-een different measured para-
meters within a group.
RESULTS
Preliminary experiments were designed
to confirm and extend the findings of
Currie and his colleagues (Currie &
Hedley, 1977) concerning the character-
istics of the maturing cells and the influ-
ence of cell numbers, excess concentration
and adherence.
The adherent cells present on Day 7
were morphologically identifiable as
macrophages by light and electron micro-
scopy. These cells stained avidly for NSE
activity, phagocytosed latex particles and
demonstrated Fc-receptor activity. Non-
adherent cells present at Day 7 were
smaller and had the characteristics of
lymphocytes. They did not show diffuse
NSE staining and were non-phagocytic.
The influence of initial cell concentra-
tion on the percentage of cells maturing to
macrophages was ascertained by plating
serial dilutions of normal mononuclear
cells in the wells and determining the
numbers maturing by Day 7. Between
initial mononuclear cell concentrations of
105/ml and 4 x 106/ml there was no signifi-
cant difference in the result obtained for
monocyte maturation in a series of 5
normal controls. This suggests that cell
density or differences in monocyte num-
bers within the initial preparations are
unlikely to influence maturation results
through overcrowding.
Optimum maturation was observed
with autologous-serum concentrations
between 40 and 65%; we chose to use a
concentration of 5000 in this study to
facilitate practical procedures, and to
enable more direct comparison with the
results ofprevious studies.
489R. G. DENT AND P. COLE
TABLEII.-Invitromononuclear-celladher-
ence and monocyte maturation
Normal
controls
1
2
3
4
Mean
SCC patients
1
2
3
4
5
6
Mean
Adherence
at 2 h
(%)
87-2
96-4
91-2
85-7
90-1
76-3
72-1
78-2
91-9
87-0
82-9
81-4
Maturation
at 7 days
(%)
47-6
49-2
56-3
39-2
48-1
7-2
23-6
6-4
24-8
36-1
15-0
17-8
Each result is the mean of 5 replicates.
In a series of 6 patients with SCC and 4
normal controls, adherence at 2 h was
measured in parallel with a determination
of monocyte maturation at Day 7 (Table
II). Although cell adherence at 2 h was
reduced in some SCC patients, there was
no consistent correlation with depressed
monocyte maturation at Day 7.
Variability ofresults
The well-to-well variation in results
was small, the coefficients of variation of
10 replicate wells being 8.5% 7-0% and
4.0% in 3 separate sets of cells. The effect
of passage of time on results was assessed
by measuring the monocyte maturation
of one normal control on 20 separate occa-
sions over 3 months. The mean result was
54-8%, with a standard deviation of 6.5%
and coefficient of variation 18.0%. Every
patient and every control subject in
Groups 1-6 was tested on 2 separate
occasions within 3 days ofeach other. The
mean difference in percent maturation
between the two occasions was 4.4 + 3.10%
for the SCC patients and 5*0 +3-8% for
the normal controls.
Monocyte maturation in autologous serum
A total of 93 controls and 40 SCC
patients has been studied. The results of
monocyte maturation in Control Groups
3-7 are given in Table III. There was no
significant difference that could be
attributed to age (Groups 3 & 4), cigarette
smoking (Groups 2 & 3) or infection
(Groups 6 & 7). There was no significant
difference between monocyte maturation
in males or females within Groups 3-7, nor
any difference between patients suffering
from COAD with normal or abnormal
respiratory function. For the purposes of
further comparison with patients and
other control groups the results of all
normal controls (Groups 3-5) and all
TABLE III.-In vitro maturation of monocytes from control groups cultured in autologous
serum
Group (n)
Normal controls
3. Non-smokers 25-35 (10)
4. Non-smokers 53-78 (10)
5. Smokers 43-75 (40)
All male controls (47)
All female controls (13)
COAD
6. Uninfected (21)
7. Infected (12)
All COAD: FEV1 or FVC <50% (14)
All COAD: FEV1 or FVC 50-75% (11)
All COAD: FEV1 and FVC > 75% (8)
Monocyte
maturation* Pt
47-8 (37-0-62-0) NS
47-0 (38-2-58-8) X
-
43-7 (30-4-56-6) }NS
46-2 (30-5-62-0)J NS
41-5 (30-4-53-0) f
39-8 (19-7-56-4) NS
34-8 (7-6-53-6) X
37-1 (7-6-56-4) f NS)
40-6 (30-4-53-2) f NS > NS
35-3 (20-1-56-4) j J
* Mean % maturation in 50% autologous serum (range).
t Significance of difference between groups assessed by Mann-Whitney U Test.
COAD =chronic obstructive airways disease.
FEV1 =forced expiratory volume in one second.
FVC =forced vital capacity.
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Fia. 1. I)@ vitro maturatioIn of monocytes
from normal controls, patients with clhronie
obstructive-airways disease (COAD)) and
patienits 'with squamous-cell carcinoma
(SCC) of the lulng. Bars represent means.
COAD patients (Groups 6 & 7) have been
combined.
The mean monocyte matturation in
COAD patients (38 0%) was lower than in
normal controls (44.90) (P < 0.05).
Maturation in patients with limited SCC
(23-9%o) and extensive SCC (14.20) was
lower than in both normal controls
(P < 0.001 ) and COAD patients (P < 0.001)
(Fig. 1). As described under Methods,
during the study each SCC patient was
matched with a relevant subject to con-
trol for any possible effect of age, sex,
cigarette smoking, infection or respiratory
function on monocyte maturation. The
results (Fig. 2) show a highly significant
difference (P < 0.001) in respect of both
limited and extensive disease.
Relationship between monocyte maturation
and clinical state of patients with SCC
Monocyte maturation in patients with
extensive disease was significantly less
P<0.001
60
50 -
I--
- 40 -
c
- 30 -
-
20
10 -
0
0
0
P<0.001
0
0
0
* <
0 I~~~~~ 0~~~~~
I
0
1
0
0
0
0@
0
C Limited C Extensive
Disease Disease
Fie. 2.- In vitro maturation of monocytes
from SCC patients and matched controls
(C). Bars represent means.
than in limited disease (P < 0.01). The size
of the primary tumour was available in
32/40 SCC patients, either from the chest
radiograph or measurement of the sur-
gically removed specimen. An analysis of
these patients revealed no correlation
between the size of the primary tumour
and monocyte maturation.
The effect of debility was assessed in
two ways. First, the level of serum
albumin in SCC patients was compared
with the result of in vitro monocyte
maturation; no correlation was found.
Second, 10 patients with serious terminal
non-malignant disease (Group 8) were
studied (Table IV). Mean maturation in
this group was 19.2%, which was signifi-
cantly lower than in normal controls
(P < 0.001.) but very similar to that in the
group ofpatients with limited malignancy.
Patients with extensive SCC had lower
maturation (14-2%) than those with
terminal non-malignant disease (19.20 °).
491
-
.R. G. DENT AND P. COLE
TABLE IV. In vitro maturation of monocytes from SCC patients and patients with
terminal non-malignant disease (NMD)
Group (n)
Normal controls (60)
Terminal NMlD (10)
Limited SCC (20)
Exten-sivXe SCC (20)
Serum
albumin (g/l)
mean + s.5(.
45-1+ 3-2
AMonocyte
maturation*
44-9 (30 4-62 0)
p
29,3 + 3-6 19-2 (3 6-42.8) < 0 001t
39.8+4 0 239 (3 7-51.6) { 0N0+
34-5 + 6-5 14-2 (2-5-52.9) { <0001t
* Mfean 0% matturation in 50()° autologous seruLm (range).
t Comparison with normal contiols.
I Comparison witlh patients withl terminal NAID.
TABLE V. Surgical resection of primary SCC in 10 males: Clinical features, operative
findings, clinical course, in vitro monocyte maturation
Involvement
of lilar
inodes Operation*
LP
LUL + BCG
RUL +RMIL
RllLL
LUL
RUL
RUL
LP
LUL
LUL
Clinical
pirogresst
NI)D (1 yr)
NDD (9 m)
Alet (6 m)
NDD (6 m)
NDD (7 m)
1) (4 m)
NDD (5 m)
NDD (1 yr)
NDI) (9 m)
NDD (6 m)
Mlonocyte
maturation+
Pre-op. Post-op.
18 45-3
5 31-5
21-1 11-2
51-6 48 0
31-3
15-3 27-4
21-7 10.0
31*3 34-8
38-5 42-0
43 0 45-8
* LP =left pneuimonectomy, LUL =left upper lobectomy, RUL =right upper lobectomy, RAMLL = right, middle and lower lobectomy; BCG =Tice strain BCG given post-operatively by intrapleural route (107
viable organisms in 1 ml).
t NDD =no clinically (letectable (lisease; D=lie(l; Mlet = metastatic liver (lisease (follow-up perio(l). + AMaturation in 5000 autologouis seruim.
Genetic influence on mionocyte maturation
To assess the possibility that SCC
patients had some genetic predisposition
for poor monocyte function, we examined
10 first-degree relatives of SCC patients
(Group 9). There was no significant differ-
ence between mean maturation in this
group, 404%o (range 34-7-51.7%o) and in
normal controls, 44.900 (30.4-6200%).
Effect of surgical resection on monocyte
maturation
Ten patients were studied longitudin-
ally. Operative findings, clinical course and
the comparison of pre- and postoperative
monocyte maturation are shown in Table
V. The monocyte maturation in normal
controls lay within the range 30.40-
6200%. If values for maturation below
30.400 are considered low, Patients 4, 5, 8,
9 and 10 in Table IV had "normal" pre-
operative values for monocyte matura-
tion. All 5 patients remained alive without
evidence of metastases or locally recurrent
disease at least 6 months postoperatively.
Postoperatively monocyte maturation was
normal in all but Patient 5. The remaining
patients had low preoperative maturation
and 3 ofthem also had a low postoperative
result. One of these has since died of his
disease and another has developed liver
metastases. Two patients with low pre-
operative maturation had normal values
after resection (Patients 1 and 2 in Table
IV); one ofthese had received intrapleural
BCG immediately after operation as part
of a trial of immunotherapy.
Patient
3
4
5
7
8
9
10(
Age
(yr)
60
51
64
62
64
67
65
71
493
69
Size of
ttumotur
(cm)
4 x 4
8 x 8
5 x 5
2 x 2
6 x 4
4 x 4
6 x6
4 x 4
:3 x 5
3 x 5
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DISCUSSION
The maturation of monocytes into
macrophages in vitro has been studied for
many years (Lewis, 1925) and there is
general agreement that in vivo maturation
of monocytes provides a sizeable propor-
tion of tissuie macrophages (Volkman,
1970). Culture of both animal and human
monocytes has been used as a source of
macrophlages suitable forin vitiro functional
studies (Blaese, 1972).
The first indication that maturation of
monocytes in vitro may be quantitatively
altered in patients with abnormalities of
the immune system appeared as a comment
in a paper by Blaese (1 972). He was study-
ing macrophage ftinction using as his
source of macrophages monocytes cul-
tured for a period of 2-17 days in vitro. He
noted that he was utnable to study
patients with 1Hodgkin's disease because
of persistently very low yields of macro-
phages. He encountered the same problem
writh cells from patients with ataxia
telangiectasia, in whom multiple defects
of the immune system have been reported.
Krikorian (1975) described an assay for
macrophage precursors in the blood, and
this has been adapted more recently by
Cuirrie & Hedley (1977) into a clinically
applicable microassay of monocyte
maturation. WN"e have been able to con-
firm some of their findings; namely,
hiigher yields using defibrinated than with
heparinized blood, lack of ainy major
variation with differing cell densities over
the range usedl in the assay, and lack of
anv co rrelation with adherence of cells
at 2 h.
In this study, normal control mono-
cytes matured in a mean percentage of
44*9 + 6*5, which compares with the nor-
mal result (48.3 + ±197) in the paper of
Taylor & Currie (I1979). The reason for the
reduced spread of the resuilts in ouir study
is unclear. Ouir results also agree with
previous w-ork, in finding no effect of age,
sex or cigarette smoking on maturation
(Currie & Hedley, 1977). We could find no
difference between COAD patients with
and without clinical infection. This is
surprising, because infection is a known
stimulus for the outpouring of monocytes
and promonocytes from marrow, and the
change in number of circulating immature
cells might reasonably be expected to
alter the number maturing in vitro. A
possible explanation may be poor identifi-
cation of patients with infection of
sufficient severity. Clinical infection based
on history and the presence of purulent
sputum is not always indicative of sys-
temic infection, and chronically infected
COAD patients do not always have
obvious clinical symptoms or signs.
SCC patients are usually smokers and
many have coexistent COAD. Because
monocyte maturation in COAD patients
was significantly less than in normal con-
trols, it was necessary to compare the
results in SCC patients with this group or
a group matched for the presence of
COAD. Both these comparisons were
made, and in each case there was signifi-
cantly depressed maturation in limited
and extensive SCC.
Depression of monocyte maturation in
50O0 autologous serum, found in SCC
patients, is similar to that described pre-
viously in patients with malignant melan-
oma (Currie & Hedley, 1977) and with
breast carcinoma (Taylor & Currie, 1979).
The deficit was more pronounced in those
with extensive disease, only 3/20 such
patients having values within the range
in normal controls, compared with 8/20
with limited disease. This is in keeping
with the findings of others (Currie &
Hedley, 1977; Taylor & Currie, 1979) that
the defect of maturation is quantitatively
related to tumour burden. It is too early
to comment in any depth on the correla-
tion of monocyte maturation with clinical
prognosis, but in respect to the effects of
surgery it is perhaps worth noting that of
the 2 subjects in whom postoperative
maturation was very low, one died after 5
months and the other developed hepatic
metastases after 6 months. The other 8
subjects studied longitudinally after sur-
gery remained well at least 6 months later,
and this includes 3 patients in whom pre-
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operative monocyte maturation was de-
pressed but returned to normal after
resection. One patient who received intra-
pleural BCG as an adjunct to surgery
showed a dramatic increase in maturation
from 5% preoperatively to 31.5% 2
months postoperatively. This is ofparticu-
lar interest in view of the dramatic in-
creases in monocyte maturation noted in
patients with malignant melanoma after
C. parvum treatment (Hedley et al., 1979).
The correlation of depression of mono-
cyte maturation with extent of disease
raises the question whether increasing
metabolic disturbance and general debility
underlie the abnormality. Such disturb-
ances may be associated with abnormali-
ties of immune function (Smythe et al.,
1971; Law et al., 1973) and macrophage
killing of micro-organisms (Olson et al.,
1978). However, although this may be
partly the cause it is unlikely to be the sole
explanation. The group of 10 patients
with terminal non-malignant disease was
chosen deliberately to represent subjects
with severe debility. Their levels ofserum
albumin were lower than those of the
group ofpatients with extensive malignant
disease (Table III), but the latter group
showed more depression of monocyte
maturation than the former. Within the
group of patients with limited and exten-
sive SCC there was no correlation ofmono-
cyte maturation with serum albumin level.
Furthermore, patients with malignancy
were tested at the time of their initial
investigation and diagnosis, when they
were not severely debilitated.
The possibility that some subjects may
be more likely to develop malignancy due
to an inherited deficiency of monocyte/
macrophage natural surveillance is attrac-
tive but we have been unable to show that
first-degree relatives of patients with SCC
were in any way different from control
subjects. Although the number ofpatients
studied was insufficient to exclude genetic
influence, therelation ofdepressedmatura-
tion to extent and size of tumour suggests
that the defect is secondary to the develop-
ment ofthe malignancy.
It ispossible that the cause forabnormal
monocyte maturation in cancer patients is
interference with normal cellular function
by soluble factors of host origin, tumour
origin, or both. Similar factors have been
described previously: for instance, mono-
cyte migration in vitro is reduced by
serum factors (Maderazo et al., 1978;
Kjeldsberg & Pay, 1978), and serum from
cancer patients may alter monocyte Fc
receptor expression (Rhodes et al., 1979)
and inhibit granulocyte-macrophage
colonv formation (Liu et al., 1979). Our
investigation of the possible soluble-factor
inhibition of monocvte maturation will be
presented in a future communication.
This investigation ofmonocyte matura-
tion in patients with squamous-cell carcin-
oma of the lung has confirmed the de-
pression found by other workers in
malignant melanoma and breast carcin-
oma. It extends the spectrum of abnor-
malities offunction found in these cells in
the presence of malignancy. This pheno-
menon may be relevant to the ability of
tumour cells to divide and metastasize
in a host despite the ability of monocytes
and macrophages to kill tumour cells in
vitro. Unfortunately, this test, like other
disturbances of immune function de-
scribed in the past, does not lend itself to
use as adiagnostic aid inearlymalignancy.
In such cases maturation is often normal
and when it is abnormal it is likely to be
less so than in those with extensive
disease. However, it may prove useful in
detecting those patients whose disease is
judged clinically to be limited, yet who are
likely to fare badly. Possibly it is a sensi-
tive marker of tumour load or spread. If
so, it may also be a more sensitive monitor
of the effect of treatment.
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